Abstract
Many study designs and design variants have been developed in the past to either overcome or enhance drug–placebo differences in clinical trials or to identify and characterize placebo responders in experimental studies. They share many commonalities as well as differences that are discussed here: the role of deception and ethical restrictions, habituation effects and the control of the natural course of disease, assay sensitivity testing and effective blinding, acceptability and motivation of patients and volunteers, and the development of individualized medicine. These are fostered by two opposite strategies: utilizing the beneficial aspects of the placebo response—and avoiding its negative counterpart, the nocebo effect—in medical routine for the benefit of patients, and minimizing—by controlling—the negative aspects of the placebo effect during drug development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amanzio M, Pollo A, Maggi G et al (2001) Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90:205–215
Aslaksen PM, Flaten MA (2008) The roles of physiological and subjective stress in the effectiveness of a placebo on experimentally induced pain. Psychosom Med 70:811–818
Aslaksen PM, Myrbakk IN, Høifødt RS et al (2007) The effect of experimenter gender on autonomic and subjective responses to pain stimuli. Pain 129:260–268
Baer L, Ivanova A (2013) When should the sequential parallel comparison design be used in clinical trials? Clin Invest 3:823–833
Benedetti F, Maggi G, Lopiano L et al (2003) Open versus hidden medical treatments: the patient’s knowledge about a therapy affects the therapy outcome. Prevention Treatment 6(1). http://psycnet.apa.org/journals/pre/6/1/1a.html. Accessed 28 Jan 2014
Benedetti F, Carlino E, Pollo A (2011) Hidden administration of drugs. Clin Pharmacol Ther 90:651–661
Bingel U, Wanigasekera V, Wiech K et al (2011) The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 3:70ra14
Boehmer J, Yong P (2009) How well does blinding work in randomized controlled trials?: a counterpoint. Clin Pharmacol Ther 85:463–465
Boutron I, Estellat C, Guittet L et al (2006) Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med 3:e425
Boutron I, Guittet L, Estellat C et al (2007) Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 4:e61
Bridge JA, Birmaher B, Iyengar S et al (2009) Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166:42–49
Colloca L, Benedetti F (2006) How prior experience shapes placebo analgesia. Pain 124:126–133
Colloca L, Benedetti F (2009) Placebo analgesia induced by social observational learning. Pain 144:28–34
Colloca L, Lopiano L, Lanotte M et al (2004) Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol 3:679–684
D’Agostino RB (2009) The delayed-start study design. N Engl J Med 361:1304–1306
De Allegri M, Pokhrel S, Becher H et al (2008) Step-wedge cluster-randomised community-based trials: an application to the study of the impact of community health insurance. Health Res Policy Syst 6:10
de la Fuente-Fernández R (2012) The powerful pre-treatment effect: placebo responses in restless legs syndrome trials. Eur J Neurol 19:1305–1310
Desai JR, Bowen EA, Danielson MM, Allam RR et al (2013) Creation and implementation of a historical controls database from randomized clinical trials. J Am Med Inform Assoc 20:e162–e168
Diener HC, Dowson AJ, Ferrari M et al (1999) Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19:699–700
Dunn AG, Mandl KD, Coiera E et al (2013) The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children. PLoS ONE 8:e84951
Edward SJ, Stevens AJ, Braunholtz DA et al (2005) The ethics of placebo-controlled trials: a comparison of inert and active placebo controls. World J Surg 29:610–614
Ehni HJ, Wiesing U (2008) International ethical regulations on placebo-use in clinical trials: a comparative analysis. Bioethics 22:64–74
Elsenbruch S, Kotsis V, Benson S et al (2012) Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders. Pain 153:382–390
Enck P, Vinson B, Malfertheiner P et al (2009) Placebo effects in functional dyspepsia – reanalysis of trial data. Neurogastroenterol Motil 21:370–377
Enck P, Klosterhalfen S, Zipfel S (2011a) Novel study designs to investigate the placebo response. BMC Med Res Methodol 11:90
Enck P, Klosterhalfen S, Weimer K et al (2011b) The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 366:1889–1895
Enck P, Grundy D, Klosterhalfen S (2012a) A novel placebo-controlled clinical study design without ethical concerns – the free choice paradigm. Med Hypotheses 79:880–882
Enck P, Horing B, Weimer K et al (2012b) Placebo responses and placebo effects in functional bowel disorders. Eur J Gastroenterol Hepatol 24:1–8
Enck P, Bingel U, Schedlowski M et al (2013) The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12:191–204
Estellat C, Ravaud P (2012) Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 172:237–244
Evans KR, Sills T, Wunderlich GR et al (2004) Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J Psychiatr Res 38:437–444
Fava M, Evins AE, Dorer DJ et al (2003) The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115–127
Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299:1898–1902
Gracely RH, Dubner R, Wolskee PJ et al (1983) Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306:264–265
Grelotti DJ, Kaptchuk TJ (2011) Placebo by proxy. BMJ 343:d4345
Hegerl U, Mergl R (2010) The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 24:445–448
Horing B (2013) Placebo effects and their prediction across multiple experimentally induced symptoms: motion sickness, cutaneous heat and cold pain, and rectal distension. Ph.D. thesis, University of Tübingen Medical School, Tübingen
Horing B, Weimer K, Muth ER et al (2014) Prediction of placebo responses: a systematic review of the literature. Front Psychol (in press)
Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602
Hróbjartsson A, Gøtzsche PC (2004) Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256:91–100
Hróbjartsson A, Forfang E, Haahr MT et al (2007) Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 36:654–663
Hunter T, Siess F, Colloca L (2013) Socially induced placebo analgesia: a comparison of a pre-recorded versus live face-to-face observation. Eur J Pain 18:914–922. doi:10.1002/j.1532-2149.2013.00436.x
Iovieno N, Papakostas GI (2012) Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/ combination strategies in treatment partial responders/nonresponders with major depressive disorder? J Clin Psychiatry 73:676–683
Ivanova A, Tamura RN (2011) A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res. doi:10.1177/0962280211431023
Ivanova A, Qaqish B, Schoenfeld DA (2011) Optimality, sample size, and power calculations for the sequential parallel comparison design. Stat Med 30:2793–2803
Kaptchuk TJ, Kelley JM, Deykin A et al (2008) Do “placebo responders” exist? Contemp Clin Trials 29:587–595
Kelemen WL, Kaighobadi F (2007) Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design. Exp Clin Psychopharmacol 15:93–101
Kessner S, Wiech K, Forkmann K et al (2013) The effect of treatment history on therapeutic outcome: an experimental approach. JAMA 173:1468–1469
King M, Nazareth I, Lampe F et al (2005) Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials. Health Technol Assess 9:1–186, iii–iv
Kirsch I (2000) Are drug and placebo effects in depression additive? Biol Psychiatry 47:733–735
Kirsch I (2005) Placebo psychotherapy: synonym or oxymoron? J Clin Psycholb 61:791–803
Kirsch I, Deacon BJ, Huedo-Medina TB et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:e45
Krogsbøll LT, Hróbjartsson A, Gøtzsche PC (2009) Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 9:1
Kunz M, Rainville P, Lautenbacher S (2011) Operant conditioning of facial displays of pain. Psychosom Med 73:422–431
Lauer MS, D’Agostino RB Sr (2013) The randomized registry trial - the next disruptive technology in clinical research? N Engl J Med 369:1579–1581
Lee S, Walker JR, Jakul L, Sexton K (2004) Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety 19:10–19
Leon AC (2012) Challenges in designing comparative-effectiveness trials for antidepressants. Clin Pharmacol Ther 91:165–167
Levine JD, Gordon NC, Fields HL (1978) The mechanism of placebo analgesia. Lancet 2:654–657
Lewis DW, Winner P, Wasiewski W (2005) The placebo responder rate in children and adolescents. Headache 45:232–239
Lidstone SC, Schulzer M, Dinelle K et al (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 67:857–865
Lindström D, Sundberg-Petersson I, Adami J et al (2010) Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial. Contemp Clin Trials 31:22–26
Lund K, Vase L, Petersen GL et al (2014) Randomised controlled trials may underestimate drug effects: balanced placebo trial design. PLoS ONE 9:e84104
Machado LA, Kamper SJ, Herbert RD et al (2008) Imperfect placebos are common in low back pain trials: a systematic review of the literature. Eur Spine J 17:889–904
Mallinckrodt CH, Zhang L, Prucka WR et al (2010) Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 43:53–72
Mangione-Smith R, McGlynn EA, Elliott MN et al (1999) The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior. Pediatrics 103:711–718
Martin AL, Katz J (2010) Inclusion of authorized deception in the informed consent process does not affect the magnitude of the placebo effect for experimentally induced pain. Pain 149:208–215
Marušić A, Ferenčić SF (2013) Adoption of the double dummy trial design to reduce observer bias in testing treatments. J R Soc Med 106:196–198
McRae AD, Weijer C, Binik A et al (2011) When is informed consent required in cluster randomized trials in health research? Trials 12:202
Metrik J, Rohsenow DJ, Monti PM et al (2009) Effectiveness of a marijuana expectancy manipulation: piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol 17:217–225
Miller FG, Wendler D, Swartzman LC (2005) Deception in research on the placebo effect. PLoS Med 2:e262
Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev:CD003012
Ney PG, Collins C, Spensor C (1986) Double blind: double talk or are there ways to do better research? Med Hypotheses 21:119–126
Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34–40
Petrovic P, Kalso E, Petersson KM et al (2002) Placebo and opioid analgesia: imaging a shared neuronal network. Science 295:1737–1740
Pollo A, Torre E, Lopiano L et al (2002) Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 13:1383–1386
Prady SL, Burch J, Crouch S et al (2013) Insufficient evidence to determine the impact of patient preferences on clinical outcomes in acupuncture trials: a systematic review. J Clin Epidemiol 66:308–318
Quilici S, Chancellor J, Löthgren M et al (2009) Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 9:6
Rao S, Lembo AJ, Shiff SJ et al (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107:1714–1724
Relton C, Torgerson D, O’Cathain A et al (2010) Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ 340:c1066
Rief W, Glombiewski JA (2012) The hidden effects of blinded, placebo-controlled randomized trials: an experimental investigation. Pain 153:2473–2477
Rief W, Nestoriuc Y, Weiss S et al (2009) Metaanalysis of the placebo response in antidepressant trials. J Affect Disord 18:1–8
Rief W, Bingel U, Schedlowski M et al (2011) Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 90:722–726
Rosenberger WF, Lachin JM (1993) The use of response-adaptive designs in clinical trials. Contemp Clin Trials 14:471–484
Rutherford BR, Sneed JR, Rosse SP (2009) Does study design influence outcome? Psychother Psychosom 78:172–181
Rutherford BR, Sneed JR, Tandler JM et al (2011) Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 50:782–795
Saarto T, Wiffen PJ (2007) Antidepressants for neuropathic pain. Cochrane Database Syst Rev:CD005454
Schmid J, Theysohn N, Gaß F et al (2013) Neural mechanisms mediating positive and negative treatment expectations in visceral pain: a functional magnetic resonance imaging study on placebo and nocebo effects in healthy volunteers. Pain 154:2372–2380
Scott DJ, Stohler CS, Egnatuk CM et al (2007) Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55:325–336
Shah E, Triantafyllou K, Hana AA et al (2013) Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogastroenterol Motil 26:482–488. doi:10.1111/nmo.12289
Sinyor M, Levitt AJ, Cheung AH et al (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71:270–279
Stone DA, Kerr CE, Jacobson E et al (2005) Patient expectations in placebo-controlled randomized clinical trials. J Eval Clin Pract 11:77–84
Suchman AL, Ader R (1992) Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 52:372–377
Swider K, Babel P (2013) The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning. Pain 154:1312–1317
Vase L, Riley JL, Price DD (2002) A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99:443–452
Vögtle E, Barke A, Kröner-Herwig B (2013) Nocebo hyperalgesia induced by social observational learning. Pain 154:1427–1433
Volkow ND, Wang GJ, Ma Y et al (2003) Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 23:11461–11468
Vray M, Girault D, Hoog-Labouret N et al (2004) Methodology for small clinical trials. Therapie 59:273–286
Weijer C, Grimshaw JM, Eccles MP et al (2012) The Ottawa statement on the ethical design and conduct of cluster randomized trials. PLoS Med 9:e1001346
Weimer K, Enck P, Klosterhalfen S (2010) Gender effects in placebo responses. Z Med Psychol 19:146–153
Weimer K, Gulewitsch M, Schlarb AA et al (2013a) Placebo effects in children: a review. Pediatr Res 74:96–102
Weimer K, Horing B, Stürmer J et al (2013b) Nicotine expectancy differentially affects reaction time in healthy non-smokers and smokers depending on gender. Exp Clin Psychopharmacol 21:181–187
Weimer K, Horing B, Walentin S et al (2013c) Nicotine stimulus expectancy but not nicotine affects cognitive performance in healthy smokers and non-smokers. Psychosom Med 75:A115
Whalley B, Hyland ME (2013) Placebo by proxy: the effect of parents’ beliefs on therapy for children’s temper tantrums. J Behav Med 36:341–346
Whalley B, Hyland ME, Kirsch I (2008) Consistency of the placebo effect. J Psychosom Res 64:537–541
Woods SW, Gueorguieva RV, Baker CB et al (2005) Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry 62:961–970
World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
Zelen M (1979) A new design for randomized clinical trials. N Engl J Med 300:1242–1245
Zhang L, Rosenberger WF (2006) Response-adaptive randomization for clinical trials with continuous outcomes. Biometrics 62:562–569
Acknowledgment
Supported by a grant from Deutsche Forschungsgemeinschaft
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Weimer, K., Enck, P. (2014). Traditional and Innovative Experimental and Clinical Trial Designs and Their Advantages and Pitfalls. In: Benedetti, F., Enck, P., Frisaldi, E., Schedlowski, M. (eds) Placebo. Handbook of Experimental Pharmacology, vol 225. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44519-8_14
Download citation
DOI: https://doi.org/10.1007/978-3-662-44519-8_14
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-44518-1
Online ISBN: 978-3-662-44519-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)